Publications
Detailed Information
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chung, Hyun Cheol | - |
dc.contributor.author | Piha-Paul, Sarina A. | - |
dc.contributor.author | Lopez-Martin, Jose | - |
dc.contributor.author | Schellens, Jan H. M. | - |
dc.contributor.author | Kao, Steven | - |
dc.contributor.author | Miller, Wilson H., Jr. | - |
dc.contributor.author | Delord, Jean-Pierre | - |
dc.contributor.author | Gao, Bo | - |
dc.contributor.author | Planchard, David | - |
dc.contributor.author | Gottfried, Maya | - |
dc.contributor.author | Zer, Alona | - |
dc.contributor.author | Jalal, Shadia I. | - |
dc.contributor.author | Penel, Nicolas | - |
dc.contributor.author | Mehnert, Janice M. | - |
dc.contributor.author | Matos, Ignacio | - |
dc.contributor.author | Bennouna, Jaafar | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Xu, Lei | - |
dc.contributor.author | Krishnan, Suba | - |
dc.contributor.author | Norwood, Kevin | - |
dc.contributor.author | Ott, Patrick A. | - |
dc.date.accessioned | 2021-01-31T08:07:14Z | - |
dc.date.available | 2021-01-31T08:07:14Z | - |
dc.date.created | 2020-05-22 | - |
dc.date.issued | 2020-04 | - |
dc.identifier.citation | Journal of Thoracic Oncology, Vol.15 No.4, pp.618-627 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.other | 101353 | - |
dc.identifier.uri | https://hdl.handle.net/10371/171823 | - |
dc.description.abstract | Introduction: Pembrolizumab has shown clinical benefit in patients with previously treated recurrent or metastatic SCLC in the phase 1b multicohort study KEYNOTE-028 (NCT02054806) and the phase 2 multicohort study KEYNOTE-158 (NCT02628067). We present a pooled analysis of patients from KEYNOTE-028 and KEYNOTE-158 who had received two or more lines of previous therapy for SCLC. Methods: Eligible patients were aged 18 years and above, had histologically or cytologically confirmed incurable recurrent or metastatic SCLC, had an Eastern Cooperative Oncology Group performance status of 1 and below, and had received two or more lines of previous therapy. Patients in KEYNOTE-028 were required to have a programmed death ligand 1 ( PD-L1)-positive tumor. Patients received pembrolizumab (10 mg/kg every 2 weeks in KEYNOTE-028 or 200 mg every 3 weeks in KEYNOTE-158) for up to 2 years. The primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1, which is presented here per independent review. Results: Eighty-three patients who had received two or more lines of previous therapy (KEYNOTE-028, n = 19; KEYNOTE-158, n = 64) were included. Median follow-up duration was 7.7 (range, 0.5-48.7) months. Objective response rate was 19.3% (95% confidence interval: 11.4-29.4); two patients had complete response (one with a PD-L1-positive tumor), and 14 patients had partial response (13 with PD-L1-positive tumors). The median duration of response was not reached (range, 4.1-35.8+ mo; plus sign indicates ongoing response); 61% of responders had responses lasting 18 months or longer. Fifty-one patients (61.4%) experienced any-grade treatment-related adverse events; eight patients (9.6%) had grade 3 or higher events. Conclusions: Pembrolizumab exhibited durable antitumor activity in a subset of patients with recurrent or metastatic SCLC who had undergone two or more previous lines of therapy, regardless of PD-L1 expression. Pembrolizumab was well tolerated. (C) 2019 Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer. | - |
dc.language | 영어 | - |
dc.publisher | Elsevier Inc. | - |
dc.title | Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.identifier.doi | 10.1016/j.jtho.2019.12.109 | - |
dc.citation.journaltitle | Journal of Thoracic Oncology | - |
dc.identifier.wosid | 000522855800024 | - |
dc.identifier.scopusid | 2-s2.0-85078181596 | - |
dc.citation.endpage | 627 | - |
dc.citation.number | 4 | - |
dc.citation.startpage | 618 | - |
dc.citation.volume | 15 | - |
dc.identifier.sci | 000522855800024 | - |
dc.description.isOpenAccess | N | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | METAANALYSIS | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Third-line therapy | - |
dc.subject.keywordAuthor | Pembrolizumab | - |
dc.subject.keywordAuthor | SCLC | - |
dc.subject.keywordAuthor | Immunotherapy | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.